Antimicrobial peptides as an alternative to anti-tuberculosis drugs

ALMATAR M., Makky E. A., YAKİCİ G., VAR I., KAYAR B., KÖKSAL F.

PHARMACOLOGICAL RESEARCH, vol.128, pp.288-305, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Review
  • Volume: 128
  • Publication Date: 2018
  • Doi Number: 10.1016/j.phrs.2017.10.011
  • Journal Name: PHARMACOLOGICAL RESEARCH
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.288-305
  • Keywords: Antimicrobial peptides (AMPs), Tuberculosis, Synergistic effect, New anti-tuberculosis drugs, D-AMINO-ACID, IN-VITRO ACTIVITY, POLYMORPHONUCLEAR LEUKOCYTE LYSOSOMES, UBIQUITIN-DERIVED PEPTIDES, HUMAN NEUTROPHIL PEPTIDE-1, HUMAN CATHELICIDIN LL-37, ALPHA-HELICAL PEPTIDES, HOST-DEFENSE PEPTIDES, S100A12 EN-RAGE, MYCOBACTERIUM-TUBERCULOSIS
  • Çukurova University Affiliated: Yes

Abstract

Tuberculosis (TB) presently accounts for high global mortality and morbidity rates, despite the introduction four decades ago of the affordable and efficient four-drugs (isoniazid, rifampicin, pyrazinamide and ethambutol). Thus, a strong need exists for new drugs with special structures and uncommon modes of action to effectively overcome M. tuberculosis. Within this scope, antimicrobial peptides (AMPs), which are small, cationic and amphipathic peptides that comprise a section of the innate immune system, are currently the leading potential agents for the treatment of TB. Many studies have recently illustrated the capability of anti-mycobacterial peptides to disrupt the normal mycobacterial cell wall function through various modes, thereby interacting with the intracellular targets, as well as encompassing nucleic acids, enzymes and organelles. This review presents a wide array of antimicrobial activities, alongside the associated properties of the AMPS that could be utilized as potential agents in therapeutic tactics for TB treatment. (C) 2017 Elsevier Ltd. All rights reserved.